pocketful logo
Ajanta Pharma Ltd logo

Ajanta Pharma Ltd

NSE: AJANTPHARM BSE: 532331

₹3048.20

(1.61%)

Wed, 18 Mar 2026, 03:08 pm

mtf coin illustrationMTF 5x

Ajanta Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    37742.43

  • Net Profit

    920.39

  • P/B

    8.66

  • Sector P/E

    31.82

  • P/E

    35.66

  • EV/EBITDA

    24.15

  • Debt/Equity (Industry)

    0.25

  • Interest Cover (Industry)

    11.42

  • ROCE (Industry)

    16.55

  • RONW (Industry)

    14.50

  • ROE

    25.02

  • ROCE

    31.98

  • Debt/Equity

    0.01

  • EPS (TTM)

    81.21

  • Dividend Yield

    0.93

  • Book Value

    345.37

  • Interest Cover

    58.36

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are well covered by earnings (4.1x coverage).
  • Dividends after 3 years are expected to be well covered by earnings (3.9x coverage).
  • Ajanta Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Ajanta Pharma's earnings growth is expected to exceed the low risk savings rate of 7.2%.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Ajanta Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Cash flow for Ajanta Pharma is expected to increase but not above the 50% threshold in 2 years time.
  • Ajanta Pharma's earnings are expected to grow by 14.3% yearly, however this is not considered high growth (20% yearly).
  • Ajanta Pharma's earnings growth is positive but not above the India market average.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters66.2566.2566.2666.2666.26
FII7.988.538.868.869.26
DII18.5817.9017.5017.4817.02
Public7.197.327.387.397.45
Government0.010.010.010.010.01

Read More

Technical Analysis

RSI

58.16

MACD

44.58

50 DMA

2873.50

200 DMA

2660.20

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic3548.473239.773116.832931.072808.132622.372313.67
Fibonacci3239.773121.843048.992931.072813.142740.292622.37
Camarilla3078.793050.493022.202931.072965.602937.312909.01

Pivots Level: Classic

R3

+617.40

3548.47

R2

+308.70

3239.77

R1

+185.77

3116.83

2931.07
2931.07
Pivot Point
LTP: 3056.60

S1

-122.93

2808.13

S2

-308.70

2622.37

S3

-617.40

2313.67

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    3013.75

  • 20-EMA

    2982.96

  • 30-EMA

    2950.50

  • 50-EMA

    2891.18

  • 100-EMA

    2792.85

  • 200-EMA

    2717.56

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
30 Jan 2026board-meetingsQuarterly Results, Nine Months Results
03 Nov 2025board-meetingsQuarterly Results, Half Yearly Results, Interim Dividend
03 Nov 2025dividend₹28.00 Dividend /Share10 Nov 2025
10 Oct 2025dividendInterim Dividend - Rs. - 2810 Nov 2025
12 Jun 2025agm
28 Oct 2024dividend₹28.00 Dividend /Share06 Nov 2024
06 Oct 2024dividendInterim Dividend - Rs. - 2806 Nov 2024
14 Jun 2024agm
02 May 2024buyback
30 Apr 2024buybackBuy Back of Shares30 May 2024

Read More

Peer Comparison

Ajanta Pharma Ltd logo

Ajanta Pharma Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Lupin Ltd logo

Lupin Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Ajanta Pharma Ltd About

Ajanta Pharma is primarily involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1979

Headquarters

CEO

Mannalal B Agrawal

Employees

Contact

Website icon

Website

http://www.ajantapharma.com

Email icon

Email

info@ajantapharma.com; investorgrievance@ajantapha

Phone icon

Phone

91-22-66061000/1204/1203

Location icon

Location

Ajanta House, Charkop Kandivli (W), Mumbai, Maharashtra, 400067

Read More

Ajanta Pharma Ltd Company History

YearHistory
2020
  • Ajanta's 1st Sterile Eye Drop Production Unit was commissioned at the Guwahati Facility.
2021
  • Ajanta Pharma was listed in the Fortune 500 list of Indian companies, ranked 379th in Revenue Generation.
2022
  • The Company issued Bonus Shares in the Ratio of 1:2.
  • Ajanta Pharma was awarded India's Best Managed Companies for 2022 by Deloitte.
  • Ajanta won the Maharashtra State Best Employer Brand Awards 2022 in the Pharma sector.
  • Ajanta won Excellence in Packaging Developed in India and Packaging Team of the Year at India Packaging Awards 2022.
2023
  • The Company proposed a buyback of its equity shares.
  • Ajanta won the Outstanding Export Performance Award from Pharmexcil in the Formulation category.
  • Ajanta won the Excellence in Pharma Supply Chain Management award.
  • Ajanta won the Times Ascent Global Best Employer Brands 2023 award.
2024
  • Ajanta Pharma was certified as a great place to work in India for the 2nd year.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
NIPPON INDIA MUTUAL FUNDBuy7154501160.122 Dec 2022
ICICI PRUDENTIAL MUTUAL FUNDBuy10861101160.122 Dec 2022
RAVI AGRAWAL TRUSTSell16388871160.122 Dec 2022
AAYUSH AGRAWAL TRUSTSell38539591160.122 Dec 2022
KOTAK MAHINDRA (INTERNATIONAL) LTDSell505977103318 Apr 2019
SBI MUTUAL FUNDBuy1357000150011 Jul 2017
GANGA EXPORTSSell24850001500.1111 Jul 2017
RAMJIDAS & SONSSell15000039817 Jan 2013
RBA FINANCE AND INVEST COBuy350000399.4417 Jan 2013
RBA FINANCE AND INVEST COBuy15000039817 Jan 2013

Read More

Ajanta Pharma Ltd News

Ajanta Pharma Promoter Updates Share Pledge Status

Aayush Agrawal, promoter of Ajanta Pharma, disclosed creation of pledge on 7,87,933 shares and release of pledge on 8,32,178 shares under SEBI regulations for loan management purposes.

06 Mar 2026

stocks

Ajanta Pharma Promoter Pledges 1.49 Lakh Shares

Promoter Aayush Agrawal pledged 1,49,000 shares of Ajanta Pharma to Bajaj Financial Securities for loan increase, raising total encumbered holding to 6.60% of share capital.

17 Feb 2026

stocks

Ajanta Pharma Denies Restaurant Brands Asia Deal Rumors

Ajanta Pharma clarifies it's not involved in Restaurant Brands Asia acquisition; promoter group's separate entity Lenexis Foodworks pursuing the deal independently.

10 Feb 2026

stocks

Ajanta Pharma Vests 4,300 SARs, Cancels 800 ESOPs

Ajanta Pharma's board committee approved vesting of 4,300 cash-settled Stock Appreciation Rights and cancellation of 800 employee stock options under its Share Based Incentive Plan 2019.

30 Jan 2026

co actions results

Ajanta Pharma Q3 Net Profit Rises 16% to ₹2.7B

Ajanta Pharma reported consolidated net profit of ₹2.7 billion for Q3, marking a 16% year-on-year growth from ₹2.33 billion in the corresponding quarter last year.

30 Jan 2026

co actions results

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800